CA67059R1091
© Globe Newswire
12.12.2025
NRX
LISTED
TSX
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
News Preview
Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s Exosomes Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s Exosomes...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.11.2025
NRX
LISTED
TSX
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter ended Septembe...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
NRX
LISTED
TSX
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
News Preview
Secures Incentive Offer of up to US$255K to Establish Operations in Indianapolis Secures Incentive Offer of up to US$255K to Establish Operations in Indianapolis...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
11.09.2025
NRX
LISTED
TSX
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
News Preview
TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to provide the following corporate updates....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
08.09.2025
NRX
LISTED
TSX
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
News Preview
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
NRX
LISTED
TSX
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
News Preview
TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the second quarter ended June 30...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
NRX
LISTED
TSX
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
News Preview
C$0.78 Million Private Placement Successfully Closed C$0.78 Million Private Placement Successfully Closed...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2025
NRX
LISTED
TSX
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
News Preview
Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound Healing Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound Healing...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
NRX
LISTED
TSX
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
News Preview
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
NRX
LISTED
TSX
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
News Preview
Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
NRX
LISTED
TSX
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
News Preview
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in B...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
NRX
LISTED
TSX
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
News Preview
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
27.05.2025
NRX
LISTED
TSX
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the first quarter ended March...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2025
NRX
LISTED
TSX
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
News Preview
NurExone Expands European Engagement with Investor Events in Germany and Switzerland...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
NRX
LISTED
TSX
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
News Preview
NurExone's Exosome-Based ExoPTEN Targets Three High-Value Nerve Injury Indications...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
NRX
LISTED
TSX
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
News Preview
TORONTO and HAIFA, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.04.2025
NRX
LISTED
TSX
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
News Preview
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.03.2025
NRX
LISTED
TSX
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
News Preview
ExoPTEN’s Preclinical Study Demonstrates Significant for Enhancing Motor Function, Increasing Blood Flow, and Faster Recovery After Spinal Cord Injuries...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.02.2025
NRX
LISTED
TSX
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
News Preview
TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting (“ISCT 2025”), a major global cell and gene therapy transl...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2025
NRX
LISTED
TSX
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
News Preview
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2025
NRX
LISTED
TSX
NurExone Biologic Secures Master Cell Bank
News Preview
NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
NRX
LISTED
TSX
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
News Preview
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.11.2024
NRX
LISTED
TSX
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
NurExone Reports Third Quarter 2024 Financial Results
and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
NRX
LISTED
TSX
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
News Preview
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.11.2024
NRX
LISTED
TSX
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
News Preview
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
NRX
LISTED
TSX
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
News Preview
NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2024
NRX
LISTED
TSX
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
News Preview
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
NRX
LISTED
TSX
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
News Preview
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.08.2024
NRX
LISTED
TSX
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
News Preview
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
NRX
LISTED
TSX
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
News Preview
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
NRX
LISTED
TSX
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
News Preview
Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
NRX
LISTED
TSX
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
News Preview
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
NRX
LISTED
TSX
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
News Preview
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice Pre...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2024
NRX
LISTED
TSX
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
News Preview
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2024
NRX
LISTED
TSX
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
News Preview
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.05.2024
NRX
LISTED
TSX
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
News Preview
NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations...
Themefolio
Profiler
Peergroup
© Newsfile
07.07.2023
NRX
LISTED
TSX
NurExone Announces Appointment of New Director and Provides Corporate Updates
News Preview
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) ("NurExone" or the "Company") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company replacing Mr. Ron Mayron, who resigned for personal reasons....
Themefolio
Profiler
Peergroup
© Newsfile
12.05.2023
NRX
LISTED
TSX
NurExone Engages Investor Relations Service Provider
News Preview
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Resea...
Themefolio
Profiler
Peergroup
© Newsfile
08.05.2023
NRX
LISTED
TSX
NurExone Announces Equity Incentive Plan Grants and Director Resignation
News Preview
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive st...
Themefolio
Profiler
Peergroup
© Newsfile
12.01.2023
NRX
LISTED
TSX
United States Patent Office Allows Patent to Exosome Biomedical Company NurExone
News Preview
The patent covers NurExone's ExoPTEN drug compositions and treatment methods for Central Nervous System diseaseHaifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy"...
Themefolio
Profiler
Peergroup
© Newsfile
15.12.2022
NRX
LISTED
TSX
NurExone Issues Annual Shareholder Letter
News Preview
Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to provide the following shareholder letter from Nur...
Themefolio
Profiler
Peergroup
© Newsfile
08.12.2022
NRX
LISTED
TSX
NurExone Announces Completion of Securites for Debt Settlement
News Preview
Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it completed its securities for...
Themefolio
Profiler
Peergroup
© Newsfile
01.12.2022
NRX
LISTED
TSX
Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
News Preview
Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapiesNurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error.Calgary, Alberta--(Newsfile Corp. - December 1, 2022) -...
Themefolio
Profiler
Peergroup
© Newsfile
30.11.2022
NRX
LISTED
TSX
NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
News Preview
Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapiesCalgary, Alberta--(Newsfile Corp. - November 30, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoThera...
Themefolio
Profiler
Peergroup
© Newsfile
25.11.2022
NRX
LISTED
TSX
NurExone Announces Securities for Debt Settlement
News Preview
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has agreed to settle debts in the amoun...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2022
NRX
LISTED
TSX
NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
News Preview
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate update and reported financial results for the quarter e...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2022
NRX
LISTED
TSX
NurExone Announces Completion of Securities for Debt Settlements
News Preview
Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities...
Themefolio
Profiler
Peergroup
© Newsfile
02.11.2022
NRX
LISTED
TSX
NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration
News Preview
The U.S. Food and Drug Administration (FDA) informed NurExone that it is at the appropriate stage of its product development for a pre-Investigational New Drug (pre-IND) meetingA pre-IND meeting could potentially shorten the regulatory timeline for the launch of NurExone's ExoTherapy into the U.S. market.Calgary, Alberta--(Newsfile Corp. - November...
Themefolio
Profiler
Peergroup
© Newsfile
26.10.2022
NRX
LISTED
TSX
NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production
News Preview
Results indicate that the proprietary production process boosts exosome productivity, improving cost-efficiencyCalgary, Alberta--(Newsfile Corp. - October 26, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients wit...
Themefolio
Profiler
Peergroup
© Newsfile
20.10.2022
NRX
LISTED
TSX
NurExone Biologic to Participate in 2022 Bio-Europe Conference
News Preview
Calgary, Alberta--(Newsfile Corp. - October 20, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company will be participating in the upcoming 2022 Bio-Europ...
Themefolio
Profiler
Peergroup
© Newsfile
12.10.2022
NRX
LISTED
TSX
UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology
News Preview
Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExon...
Themefolio
Profiler
Peergroup
© Newsfile
12.10.2022
NRX
LISTED
TSX
NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology
News Preview
Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExon...
Themefolio
Profiler
Peergroup
© Newsfile
04.10.2022
NRX
LISTED
TSX
NurExone Announces Scientific Survey Results of Proprietary Exosome-based Technology
News Preview
Results show a significant increase in effectiveness of NurExone's therapeutic compounds in inhibition of PTEN expressionCalgary, Alberta--(Newsfile Corp. - October 4, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for pat...
Themefolio
Profiler
Peergroup
© Newsfile
03.10.2022
NRX
LISTED
TSX
NurExone Announces Additional Securities for Debt Settlement
News Preview
Calgary, Alberta--(Newsfile Corp. - October 3, 2022) - Further to our news release of September 1, 2022, NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is...
Themefolio
Profiler
Peergroup
© Newsfile
07.09.2022
NRX
LISTED
TSX
NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome Production
News Preview
Calgary, Alberta, Canada and Dresden, Germany--(Newsfile Corp. - September 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is pleased to announce that the Company has entered into a letter of...
Themefolio
Profiler
Peergroup
© Newsfile
01.09.2022
NRX
LISTED
TSX
NurExone Announces Securities Issuing at Premium over Current Share Price to Settle EnerSpar's Debts Prior to RTO Transaction
News Preview
Calgary, Alberta--(Newsfile Corp. - September 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares...
Themefolio
Profiler
Peergroup
© Newsfile
25.08.2022
NRX
LISTED
TSX
NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update
News Preview
Calgary, Alberta--(Newsfile Corp. - August 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients suffering from traumatic spinal cord injuries, released a business update and reported financial results for the q...
Themefolio
Profiler
Peergroup
© Newsfile
09.08.2022
NRX
LISTED
TSX
James Richardson, the Former CEO of EnerSpar, Updates Shareholders After the Completion of RTO with NurExone Biologic
News Preview
Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, released excerpts from a letter uploaded to Sedar today from Mr. Jay Richardson, For...
Themefolio
Profiler
Peergroup
© Newsfile
25.07.2022
NRX
LISTED
TSX
NurExone Announces Sponsorship and Participation in Gordon Research's 2022 Extracellular Vesicles Conference in Maine, U.S.
News Preview
Calgary, Alberta--(Newsfile Corp. - July 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) ("NurExone" or the "Company"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System ("CNS") indications, is pleased to announce that it will showcase a poster pres...
Themefolio
Profiler
Peergroup
© Newsfile
19.07.2022
NRX
LISTED
TSX
NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University's Burstyn-Cohen Lab
News Preview
Calgary, Alberta--(Newsfile Corp. - July 19, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System ("CNS") indications, announced the si...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
